ArticleAIDS and behavior2013
Rural residence and adoption of a novel HIV therapy in a national, equal-access healthcare system.
Article in AIDS and behavior, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.BMC health services research · 2021Pooled it
- Barriers to care for rural people living with HIV: a review of domestic research and health care models.The Journal of the Association of Nurses in AIDS Care : JANACPooled it
- Trial
- Distance as a barrier to HIV testing among sexual and gender minority populations in the rural southern US: a cross-sectional study.Rural and remote health · 2023Article
- Article
- Human Immunodeficiency Virus (HIV) and Aging: Multimorbidity in Older People With HIV in One Nonurban Southeastern Ryan White HIV/AIDS Program Clinic.Open forum infectious diseases · 2021Article
- Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus: The Veteran Birth Cohort.Medical care · 2019Observational
- Washington state satellite HIV clinic program: a model for delivering highly effective decentralized care in under-resourced communities.AIDS care · 2018Article
- Article
- Innovative technologies and social inequalities in health: A scoping review of the literature.PloS one · 2018Article
- An Evidence Map of the Women Veterans' Health Research Literature (2008-2015).Journal of general internal medicine · 2017Review
- The Continuum of HIV Care in Rural Communities in the United States and Canada: What Is Known and Future Research Directions.Journal of acquired immune deficiency syndromes (1999) · 2017Review
- Impact of a Telehealth Program That Delivers Remote Consultation and Longitudinal Mentorship to Community HIV Providers.Open forum infectious diseases · 2016Article
- Access to CD4 Testing for Rural HIV Patients: Findings from a Cohort Study in Zimbabwe.PloS one · 2015Article
- Examining Multilevel Factors Associated with the Process of Resilience among Women Living with HIV in a Large Canadian Cohort Study: A Structural Equation Modeling Approach.Journal of the International Association of Providers of AIDS CareArticle
- Article
- Development of the Canadian Women-Centred HIV Care Model Using the Knowledge-to-Action Framework.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Rural persons with HIV face barriers to care that may influence adoption of advances in therapy. We performed a retrospective cohort study to determine rural-urban variation in adoption of raltegravir-the first HIV integrase inhibitor-in national Veterans Affairs (VA) healthcare. There were 1,222 veterans with clinical indication for raltegravir therapy at time of its FDA approval in October 2007, of whom 223 (19.1%) resided in rural areas. Urban persons were more likely than rural to initiate raltegravir within 180 days (17.3% vs. 11.2%, P = 0.02) and 360 days (27.5% vs. 19.7%, P = 0.02), but this gap narrowed slightly at 720 days (36.3% vs. 31.8%, P = 0.19). In multivariable analysis adjusting for patient characteristics, urban residence predicted raltegravir adoption within 180 days (odds ratio 1.72, 95% CI 1.09-2.70) and 360 days (OR 1.63, 95% CI 1.13-2.34), but not 720 days (OR 1.26, 95% CI 0.84-1.87). Efforts are needed to reduce geographic variation in adoption of advances in HIV therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.